{"transactions":[{"id":729046,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2026-06-23T21:20:42.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":14950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."}],"balance_after":14950,"derivative":{"exercise_price":34.16,"expiration_date":"2036-06-18","underlying":"Common stock","underlying_shares":14950},"source":{"system":"sec-edgar","filing":"0001439222-26-000095","document":"wk-form4_1782249639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000095/wk-form4_1782249639.xml","form_type":"4"}},{"id":729045,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:20:42.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":2927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2927,"derivative":{"underlying":"Common stock","underlying_shares":2927},"source":{"system":"sec-edgar","filing":"0001439222-26-000095","document":"wk-form4_1782249639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000095/wk-form4_1782249639.xml","form_type":"4"}},{"id":729044,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2026-06-23T21:20:42.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-26-000095","document":"wk-form4_1782249639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000095/wk-form4_1782249639.xml","form_type":"4"}},{"id":729043,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2026-06-23T21:20:42.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20419,"source":{"system":"sec-edgar","filing":"0001439222-26-000095","document":"wk-form4_1782249639.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922226000095/wk-form4_1782249639.xml","form_type":"4"}},{"id":730010,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2026-06-22T20:29:33.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":51700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027."}],"balance_after":51700,"derivative":{"exercise_price":2.55,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":51700},"source":{"system":"sec-edgar","filing":"0001650664-26-000069","document":"wk-form4_1782160170.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000069/wk-form4_1782160170.xml","form_type":"4"}},{"id":998813,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-11-14T21:04:55.000Z","date":"2025-11-12","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date."}],"balance_after":26907,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001439222-25-000120","document":"wk-form4_1763154293.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000120/wk-form4_1763154293.xml","form_type":"4"}},{"id":998812,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-11-14T21:04:55.000Z","date":"2025-11-12","kind":"sale","planned":true,"acquired":false,"shares":200,"price":43.84,"value":8768.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17603,"source":{"system":"sec-edgar","filing":"0001439222-25-000120","document":"wk-form4_1763154293.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000120/wk-form4_1763154293.xml","form_type":"4"}},{"id":998811,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-11-14T21:04:55.000Z","date":"2025-11-12","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":18.09,"value":3618.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17803,"source":{"system":"sec-edgar","filing":"0001439222-25-000120","document":"wk-form4_1763154293.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000120/wk-form4_1763154293.xml","form_type":"4"}},{"id":1020213,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-10-10T20:18:07.000Z","date":"2025-10-08","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date."}],"balance_after":27107,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001439222-25-000108","document":"wk-form4_1760127484.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000108/wk-form4_1760127484.xml","form_type":"4"}},{"id":1020212,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-10-10T20:18:07.000Z","date":"2025-10-08","kind":"sale","planned":true,"acquired":false,"shares":200,"price":41,"value":8200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17603,"source":{"system":"sec-edgar","filing":"0001439222-25-000108","document":"wk-form4_1760127484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000108/wk-form4_1760127484.xml","form_type":"4"}},{"id":1020211,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-10-10T20:18:07.000Z","date":"2025-10-08","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":18.09,"value":3618.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17803,"source":{"system":"sec-edgar","filing":"0001439222-25-000108","document":"wk-form4_1760127484.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000108/wk-form4_1760127484.xml","form_type":"4"}},{"id":1027064,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-10-02T20:03:54.000Z","date":"2025-09-30","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date."}],"balance_after":27307,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001439222-25-000106","document":"wk-form4_1759435431.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000106/wk-form4_1759435431.xml","form_type":"4"}},{"id":1027063,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-10-02T20:03:54.000Z","date":"2025-09-30","kind":"sale","planned":true,"acquired":false,"shares":200,"price":40,"value":8000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17603,"source":{"system":"sec-edgar","filing":"0001439222-25-000106","document":"wk-form4_1759435431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000106/wk-form4_1759435431.xml","form_type":"4"}},{"id":1027062,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-10-02T20:03:54.000Z","date":"2025-09-30","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":18.09,"value":3618.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17803,"source":{"system":"sec-edgar","filing":"0001439222-25-000106","document":"wk-form4_1759435431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000106/wk-form4_1759435431.xml","form_type":"4"}},{"id":1052817,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-08-29T20:09:02.000Z","date":"2025-08-27","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date."}],"balance_after":27507,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001439222-25-000100","document":"wk-form4_1756498139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000100/wk-form4_1756498139.xml","form_type":"4"}},{"id":1052816,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-08-29T20:09:02.000Z","date":"2025-08-27","kind":"sale","planned":true,"acquired":false,"shares":200,"price":40,"value":8000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17603,"source":{"system":"sec-edgar","filing":"0001439222-25-000100","document":"wk-form4_1756498139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000100/wk-form4_1756498139.xml","form_type":"4"}},{"id":1052815,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-08-29T20:09:02.000Z","date":"2025-08-27","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":18.09,"value":3618.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17803,"source":{"system":"sec-edgar","filing":"0001439222-25-000100","document":"wk-form4_1756498139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000100/wk-form4_1756498139.xml","form_type":"4"}},{"id":1087330,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-07-15T20:05:59.000Z","date":"2025-07-10","kind":"exercise","planned":true,"acquired":false,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date."}],"balance_after":27707,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001439222-25-000084","document":"wk-form4_1752609950.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000084/wk-form4_1752609950.xml","form_type":"4"}},{"id":1087329,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-07-15T20:05:59.000Z","date":"2025-07-10","kind":"sale","planned":true,"acquired":false,"shares":1400,"price":40,"value":56000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17603,"source":{"system":"sec-edgar","filing":"0001439222-25-000084","document":"wk-form4_1752609950.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000084/wk-form4_1752609950.xml","form_type":"4"}},{"id":1087328,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-07-15T20:05:59.000Z","date":"2025-07-10","kind":"exercise","planned":true,"acquired":true,"shares":1400,"price":18.09,"value":25326.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19003,"source":{"system":"sec-edgar","filing":"0001439222-25-000084","document":"wk-form4_1752609950.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000084/wk-form4_1752609950.xml","form_type":"4"}},{"id":1103649,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2025-06-23T20:18:55.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2120},"source":{"system":"sec-edgar","filing":"0001439222-25-000049","document":"wk-form4_1750709929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000049/wk-form4_1750709929.xml","form_type":"4"}},{"id":1103648,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2025-06-23T20:18:55.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":15768,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options were granted on June 18, 2025. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2026."}],"balance_after":15768,"derivative":{"exercise_price":35.5,"expiration_date":"2035-06-18","underlying":"Common stock","underlying_shares":15768},"source":{"system":"sec-edgar","filing":"0001439222-25-000049","document":"wk-form4_1750709929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000049/wk-form4_1750709929.xml","form_type":"4"}},{"id":1103647,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2025-06-23T20:18:55.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":2816,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2816,"derivative":{"underlying":"Common stock","underlying_shares":2816},"source":{"system":"sec-edgar","filing":"0001439222-25-000049","document":"wk-form4_1750709929.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000049/wk-form4_1750709929.xml","form_type":"4"}},{"id":1103646,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2025-06-23T20:18:55.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":17603,"source":{"system":"sec-edgar","filing":"0001439222-25-000049","document":"wk-form4_1750709929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922225000049/wk-form4_1750709929.xml","form_type":"4"}},{"id":1115974,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2025-06-10T20:19:16.000Z","date":"2025-06-06","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026."}],"balance_after":37500,"derivative":{"exercise_price":1.91,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001650664-25-000102","document":"wk-form4_1749586749.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000102/wk-form4_1749586749.xml","form_type":"4"}},{"id":1332225,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2024-12-13T21:04:41.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date."}],"balance_after":29107,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001439222-24-000146","document":"wk-form4_1734123872.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000146/wk-form4_1734123872.xml","form_type":"4"}},{"id":1332224,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-12-13T21:04:41.000Z","date":"2024-12-11","kind":"sale","planned":true,"acquired":false,"shares":200,"price":46.28,"value":9256.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":15483,"source":{"system":"sec-edgar","filing":"0001439222-24-000146","document":"wk-form4_1734123872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000146/wk-form4_1734123872.xml","form_type":"4"}},{"id":1332223,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-12-13T21:04:41.000Z","date":"2024-12-11","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":18.09,"value":3618.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":15683,"source":{"system":"sec-edgar","filing":"0001439222-24-000146","document":"wk-form4_1734123872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000146/wk-form4_1734123872.xml","form_type":"4"}},{"id":1465735,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T19:17:33.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":38700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest over three years in equal monthly installments following July 1, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date."}],"balance_after":38700,"derivative":{"exercise_price":1.67,"expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":38700},"source":{"system":"sec-edgar","filing":"0001104659-24-076987","document":"tm2418517-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924076987/tm2418517-3_4seq1.xml","form_type":"4"}},{"id":1470587,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2024-06-24T20:09:28.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":11774,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 20, 2024. The shares underlying this option vest as to 100% of the underlying shares on June 20, 2025."}],"balance_after":11774,"derivative":{"exercise_price":42.45,"expiration_date":"2034-06-20","underlying":"Common stock","underlying_shares":11774},"source":{"system":"sec-edgar","filing":"0001439222-24-000101","document":"wk-form4_1719259761.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000101/wk-form4_1719259761.xml","form_type":"4"}},{"id":1470586,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-06-24T20:09:28.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":2120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 20, 2024. The shares underlying the stock units will vest in full on June 20, 2025. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2120,"derivative":{"underlying":"Common stock","underlying_shares":2120},"source":{"system":"sec-edgar","filing":"0001439222-24-000101","document":"wk-form4_1719259761.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000101/wk-form4_1719259761.xml","form_type":"4"}},{"id":1477200,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2024-06-17T21:18:14.000Z","date":"2024-06-13","kind":"exercise","planned":false,"acquired":false,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":3388},"source":{"system":"sec-edgar","filing":"0001439222-24-000079","document":"wk-form4_1718659086.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000079/wk-form4_1718659086.xml","form_type":"4"}},{"id":1477199,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2024-06-17T21:18:14.000Z","date":"2024-06-13","kind":"exercise","planned":false,"acquired":true,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15483,"source":{"system":"sec-edgar","filing":"0001439222-24-000079","document":"wk-form4_1718659086.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922224000079/wk-form4_1718659086.xml","form_type":"4"}},{"id":1494755,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to  buy)","published_at":"2024-06-03T21:15:27.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025"}],"balance_after":25000,"derivative":{"exercise_price":5.17,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001650664-24-000072","document":"wk-form4_1717449318.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000072/wk-form4_1717449318.xml","form_type":"4"}},{"id":1845091,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2023-06-23T20:36:02.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":4975},"source":{"system":"sec-edgar","filing":"0001439222-23-000093","document":"wk-form4_1687552551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000093/wk-form4_1687552551.xml","form_type":"4"}},{"id":1845090,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-06-23T20:36:02.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":12095,"source":{"system":"sec-edgar","filing":"0001439222-23-000093","document":"wk-form4_1687552551.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000093/wk-form4_1687552551.xml","form_type":"4"}},{"id":1854215,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2023-06-15T20:28:08.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":18958,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 13, 2023. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2024."}],"balance_after":18958,"derivative":{"exercise_price":26.56,"expiration_date":"2033-06-13","underlying":"Common stock","underlying_shares":18958},"source":{"system":"sec-edgar","filing":"0001439222-23-000083","document":"wk-form4_1686860874.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000083/wk-form4_1686860874.xml","form_type":"4"}},{"id":1854214,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2023-06-15T20:28:08.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":3388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 13, 2023. The shares underlying the stock units will vest in full on June 13, 2024. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":3388,"derivative":{"underlying":"Common stock","underlying_shares":3388},"source":{"system":"sec-edgar","filing":"0001439222-23-000083","document":"wk-form4_1686860874.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000083/wk-form4_1686860874.xml","form_type":"4"}},{"id":1866068,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T20:30:24.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 1, 2023 and is scheduled to vest in full on June 1, 2024."}],"balance_after":25000,"derivative":{"exercise_price":9.55,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-23-009233","document":"form4-06052023_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588923009233/form4-06052023_040614.xml","form_type":"4"}},{"id":2218696,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-30T22:33:55.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 28, 2023 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":20000,"derivative":{"exercise_price":1.21,"expiration_date":"2032-06-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-024670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924322024670/doc4.xml","form_type":"4"}},{"id":2222985,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2022-06-23T20:11:38.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":29307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023."}],"balance_after":29307,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":29307},"source":{"system":"sec-edgar","filing":"0001439222-22-000065","document":"wf-form4_165601507916195.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000065/wf-form4_165601507916195.xml","form_type":"4"}},{"id":2222984,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2022-06-23T20:11:38.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":4975,"derivative":{"underlying":"Common stock","underlying_shares":4975},"source":{"system":"sec-edgar","filing":"0001439222-22-000065","document":"wf-form4_165601507916195.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000065/wf-form4_165601507916195.xml","form_type":"4"}},{"id":2233632,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-13T20:30:28.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 9, 2022 and is scheduled to vest in full on June 9, 2023."}],"balance_after":25000,"derivative":{"exercise_price":12.31,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-22-006491","document":"form4-06132022_040616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000141588922006491/form4-06132022_040616.xml","form_type":"4"}},{"id":2258115,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2022-05-24T20:12:33.000Z","date":"2022-05-20","kind":"exercise","acquired":false,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001439222-22-000053","document":"wf-form4_165342313322648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000053/wf-form4_165342313322648.xml","form_type":"4"}},{"id":2258114,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2022-05-24T20:12:33.000Z","date":"2022-05-20","kind":"exercise","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7120,"source":{"system":"sec-edgar","filing":"0001439222-22-000053","document":"wf-form4_165342313322648.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000053/wf-form4_165342313322648.xml","form_type":"4"}},{"id":2678742,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-07T20:14:09.000Z","date":"2021-06-03","kind":"grant","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 3, 2021 and is scheduled to vest in full on June 3, 2022."}],"balance_after":11538,"derivative":{"exercise_price":33.36,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001179110-21-006454","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000117911021006454/edgar.xml","form_type":"4"}},{"id":2683362,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-03T22:30:52.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":18188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 1, 2022 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":18188,"derivative":{"exercise_price":12.91,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":18188},"source":{"system":"sec-edgar","filing":"0000899243-21-021839","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924321021839/doc4.xml","form_type":"4"}},{"id":2686290,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2021-06-02T20:07:30.000Z","date":"2021-05-28","kind":"exercise","acquired":false,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1686},"source":{"system":"sec-edgar","filing":"0001439222-21-000051","document":"wf-form4_162266443793602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000051/wf-form4_162266443793602.xml","form_type":"4"}},{"id":2686289,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-06-02T20:07:30.000Z","date":"2021-05-28","kind":"exercise","acquired":true,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5535,"source":{"system":"sec-edgar","filing":"0001439222-21-000051","document":"wf-form4_162266443793602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000051/wf-form4_162266443793602.xml","form_type":"4"}},{"id":2698759,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2021-05-24T20:46:09.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022."}],"balance_after":8888,"derivative":{"exercise_price":56.76,"expiration_date":"2031-05-20","underlying":"Common stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001439222-21-000048","document":"wf-form4_162188914901072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000048/wf-form4_162188914901072.xml","form_type":"4"}},{"id":2698758,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2021-05-24T20:46:09.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"}],"balance_after":1585,"derivative":{"underlying":"Common stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001439222-21-000048","document":"wf-form4_162188914901072.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000048/wf-form4_162188914901072.xml","form_type":"4"}},{"id":3111407,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-12T20:11:56.000Z","date":"2020-06-10","kind":"grant","acquired":true,"shares":11538,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 10, 2020 and is scheduled to vest on June 10, 2021."}],"balance_after":11538,"derivative":{"exercise_price":27.49,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":11538},"source":{"system":"sec-edgar","filing":"0001179110-20-007263","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000117911020007263/edgar.xml","form_type":"4"}},{"id":3116449,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-09T20:22:09.000Z","date":"2020-06-05","kind":"grant","acquired":true,"shares":18188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 5, 2021 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":18188,"derivative":{"exercise_price":9.99,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":18188},"source":{"system":"sec-edgar","filing":"0000899243-20-015790","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924320015790/doc4.xml","form_type":"4"}},{"id":3128965,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-06-01T21:14:20.000Z","date":"2020-05-29","kind":"exercise","acquired":false,"shares":1878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1878},"source":{"system":"sec-edgar","filing":"0001439222-20-000054","document":"wf-form4_159104604311997.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000054/wf-form4_159104604311997.xml","form_type":"4"}},{"id":3128964,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2020-06-01T21:14:20.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."}],"balance_after":1686,"derivative":{"underlying":"Common stock","underlying_shares":1686},"source":{"system":"sec-edgar","filing":"0001439222-20-000054","document":"wf-form4_159104604311997.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000054/wf-form4_159104604311997.xml","form_type":"4"}},{"id":3128963,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2020-06-01T21:14:20.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":8096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 28, 2020. This option vests as to 100% of the underlying shares on May 28, 2021."}],"balance_after":8096,"derivative":{"exercise_price":53.35,"expiration_date":"2030-05-28","underlying":"Common stock","underlying_shares":8096},"source":{"system":"sec-edgar","filing":"0001439222-20-000054","document":"wf-form4_159104604311997.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000054/wf-form4_159104604311997.xml","form_type":"4"}},{"id":3128962,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2020-06-01T21:14:20.000Z","date":"2020-05-29","kind":"exercise","acquired":true,"shares":1878,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":3849,"source":{"system":"sec-edgar","filing":"0001439222-20-000054","document":"wf-form4_159104604311997.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000054/wf-form4_159104604311997.xml","form_type":"4"}},{"id":3494328,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-11T21:12:29.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":18188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (a) June 7, 2020 or (b) the next annual meeting of the Issuer's stockholders."}],"balance_after":18188,"derivative":{"exercise_price":13.4,"expiration_date":"2029-06-06","underlying":"Common Stock","underlying_shares":18188},"source":{"system":"sec-edgar","filing":"0000899243-19-016419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924319016419/doc4.xml","form_type":"4"}},{"id":3506286,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2019-05-31T20:08:56.000Z","date":"2019-05-31","kind":"exercise","acquired":false,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on May 31, 2018. The shares underlying the stock units vested in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001209191-19-033626","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119033626/doc4.xml","form_type":"4"}},{"id":3506285,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2019-05-31T20:08:56.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":1878,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on May 29, 2019. The shares underlying the stock units will vest in full on May 29, 2020. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":1878,"derivative":{"underlying":"Common stock","underlying_shares":1878},"source":{"system":"sec-edgar","filing":"0001209191-19-033626","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119033626/doc4.xml","form_type":"4"}},{"id":3506284,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-05-31T20:08:56.000Z","date":"2019-05-29","kind":"grant","acquired":true,"shares":8919,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 29, 2019. The shares underlying this option vest as to 100% of the underlying shares on May 29, 2020."}],"balance_after":8919,"derivative":{"exercise_price":47.91,"expiration_date":"2029-05-29","underlying":"Common stock","underlying_shares":8919},"source":{"system":"sec-edgar","filing":"0001209191-19-033626","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119033626/doc4.xml","form_type":"4"}},{"id":3506283,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2019-05-31T20:08:56.000Z","date":"2019-05-31","kind":"exercise","acquired":true,"shares":1400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":1971,"source":{"system":"sec-edgar","filing":"0001209191-19-033626","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119033626/doc4.xml","form_type":"4"}},{"id":3669997,"issuer":{"id":5502,"kind":"organization","name":"Editas Medicine, Inc.","symbol":"EDIT"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-02-07T21:41:04.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":23076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 5, 2019 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on February 5, 2020 through February 5, 2022."}],"balance_after":23076,"derivative":{"exercise_price":21.14,"expiration_date":"2029-02-04","underlying":"Common Stock","underlying_shares":23076},"source":{"system":"sec-edgar","filing":"0001179110-19-001519","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650664/000117911019001519/edgar.xml","form_type":"4"}},{"id":3882381,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-06-27T20:36:21.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":16094,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6228},"source":{"system":"sec-edgar","filing":"0000899243-18-018341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924318018341/doc4.xml","form_type":"4"}},{"id":3882380,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-06-27T20:36:21.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":6429,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2488},"source":{"system":"sec-edgar","filing":"0000899243-18-018341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924318018341/doc4.xml","form_type":"4"}},{"id":3882379,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2018-06-27T20:36:21.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":50025,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19360},"source":{"system":"sec-edgar","filing":"0000899243-18-018341","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924318018341/doc4.xml","form_type":"4"}},{"id":3882378,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T20:36:21.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":6600,"price":15,"value":99000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects shares that were purchased through a directed share program in connection with the Issuer's initial public offering."}],"balance_after":228175,"source":{"system":"sec-edgar","filing":"0000899243-18-018341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924318018341/doc4.xml","form_type":"4"}},{"id":3882377,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-27T20:36:21.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":28076,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the \"Preferred Stock\") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date."}],"balance_after":221575,"source":{"system":"sec-edgar","filing":"0000899243-18-018341","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924318018341/doc4.xml","form_type":"4"}},{"id":3908246,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2018-06-04T20:28:00.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":1400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":1400,"derivative":{"underlying":"Common stock","underlying_shares":1400},"source":{"system":"sec-edgar","filing":"0001209191-18-035091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118035091/doc4.xml","form_type":"4"}},{"id":3908245,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2018-06-04T20:28:00.000Z","date":"2018-05-31","kind":"grant","acquired":true,"shares":5700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019."}],"balance_after":5700,"derivative":{"exercise_price":93.5,"expiration_date":"2028-05-30","underlying":"Common stock","underlying_shares":5700},"source":{"system":"sec-edgar","filing":"0001209191-18-035091","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118035091/doc4.xml","form_type":"4"}},{"id":3987489,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2018-03-20T20:43:15.000Z","date":"2018-03-16","kind":"purchase","acquired":true,"shares":200,"price":83.44,"value":16688.0,"ownership":{"direct":true},"balance_after":571,"source":{"system":"sec-edgar","filing":"0001209191-18-020896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118020896/doc4.xml","form_type":"4"}},{"id":4280653,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-06-15T21:06:15.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 13, 2017. The shares underlying this option vest as to 100% of the underlying shares on June 13, 2018."}],"balance_after":8000,"derivative":{"exercise_price":50.73,"expiration_date":"2027-06-12","underlying":"Common stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-17-040194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919117040194/doc4.xml","form_type":"4"}},{"id":4299743,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":35959,"kind":"person","name":"Scadden David","position":1,"cik":"0001707715","reported_name":"Scadden David","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2017-05-31T20:38:19.000Z","date":"2017-05-27","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 27, 2017. The shares underlying this option vest as to 25% of the underlying shares on May 27, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":16000,"derivative":{"exercise_price":48.2,"expiration_date":"2027-05-26","underlying":"Common stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001209191-17-036461","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919117036461/doc4.xml","form_type":"4"}}]}